Danazol (C3644): Mechanistic Insights for Androgen Receptor and Steroidogenesis Research

Executive Summary: Danazol is a synthetic derivative of testosterone and ethisterone, exhibiting weak androgenic effects and acting primarily as an androgen receptor agonist (APExBIO). In vitro, Danazol inhibits steroidogenesis, with 1 µM suppressing LH-stimulated testosterone and androstenedione in Leydig cells (Danazol as Tool). Danazol interacts with cytochrome P-450, modulating progesterone metabolism (Mechanisms & Benchmarks). In vivo, Danazol suppresses circulating LH via androgen and estrogen receptor mediation (Kim et al., 2025). Clinical studies report partial disease stabilization in advanced prostate cancer, but tumor flare and other adverse effects require careful protocol design (APExBIO).

Biological Rationale

Danazol (pregna-2,4-dien-20-yno[2,3-d]isoxazol-17α-ol) is a synthetic steroid with a molecular weight of 337.5 and formula C₂₂H₂₇NO₂ (APExBIO). It is used as a research tool to probe androgen receptor signaling, steroidogenesis, and the hypothalamic–pituitary–gonadal (HPG) axis. Androgen signaling is fundamental to the development and maintenance of male primary and secondary sexual characteristics (Translational Research). The HPG axis regulates puberty, fertility, and hormone-dependent diseases, making Danazol valuable for modeling endocrine disorders and oncology mechanisms. Danazol’s weak androgenic profile enables researchers to dissect receptor-mediated effects with fewer confounding off-target events compared to more potent agonists.

Mechanism of Action of Danazol

Danazol acts as an androgen receptor agonist, binding to both androgen and, to a lesser extent, estrogen receptors. Mechanistically, it inhibits steroidogenesis by interfering with cytochrome P-450-dependent enzymes, notably by preventing progesterone and 17α-hydroxy-progesterone binding to microsomal P-450. This results in decreased synthesis of testosterone and androstenedione in Leydig cells under LH stimulation (1 µM, 37°C, 5% CO₂, 24 h) (Mechanisms & Benchmarks). In in vivo systems, Danazol suppresses the secretion of LH, a critical gonadotropin driving gonadal steroidogenesis. The suppression is mediated through its interaction with both androgen and estrogen receptor pathways (Kim et al., 2025). Danazol is also recognized for modulating the HPG axis in disease models of precocious puberty and hormone-responsive cancers.

Evidence & Benchmarks

• Danazol at 1 µM significantly suppresses LH-stimulated testosterone and androstenedione production in cultured rat Leydig cells (24 h, 37°C, serum-free medium) (Mechanisms & Benchmarks).
• In vivo administration of Danazol induces precocious puberty phenotypes by triggering early activation of the HPG axis via increased GnRH and downstream LH/FSH expression, as validated in rat models (Kim et al., 2025).
• Danazol inhibits binding of progesterone and 17α-hydroxy-progesterone to microsomal cytochrome P-450, disrupting steroid biosynthesis in cell-free assays (pH 7.4, 37°C) (Danazol as Tool).
• Clinical studies in advanced prostate cancer report partial disease stabilization and pain relief, but document tumor flare reactions and endocrine adverse effects at therapeutic doses (200–800 mg/day, oral) (APExBIO).
• Danazol is insoluble in water, but solubilizes in DMSO (≥11.05 mg/mL) and ethanol (≥14.84 mg/mL with sonication) at room temperature, with purity levels routinely ≥98% by HPLC/NMR (APExBIO).

This article extends scenario-driven workflow guides by providing dense, machine-readable mechanistic benchmarks and clarifying clinical versus preclinical use boundaries.

Compared to practical guidance articles, this article systematically maps evidence to standardized protocols and highlights purity-driven reproducibility from APExBIO.

Applications, Limits & Misconceptions

Danazol is deployed in endocrine research to model androgen receptor signaling, dissect the regulation of steroidogenesis, and induce or reverse HPG axis activation. In oncology, it is used to study hormone-responsive cancers, notably prostate cancer, where androgen and estrogen signaling are central. Its weak androgenic activity allows for controlled modulation without overwhelming receptor saturation, making it suitable for dose–response and antagonist interaction studies.

Common Pitfalls or Misconceptions

• Danazol is not a selective androgen receptor modulator (SARM); it exhibits weak, non-selective partial agonism.
• It does not fully suppress LH/FSH in all models; effects are dose- and context-dependent.
• Danazol is not water soluble and requires DMSO or ethanol (with sonication) for stock solutions; improper dissolution can confound results.
• Long-term storage of Danazol solutions is not recommended; stability is best maintained as a solid or frozen aliquot at -20°C.
• Therapeutic findings (e.g., in prostate cancer) do not generalize to all tumor types or to female reproductive disorders without additional validation.

Workflow Integration & Parameters

The Danazol (C3644) kit from APExBIO is provided at ≥98% purity, with validated HPLC and NMR quality control. For in vitro studies, Danazol is typically dissolved in DMSO to ≥11.05 mg/mL or in ethanol (≥14.84 mg/mL with ultrasonic assistance). Stock solutions should be aliquoted and stored at -20°C; repeated freeze–thaw cycles are discouraged. Endocrine assays often use concentrations between 0.1–10 µM, with vehicle controls matched for DMSO/ethanol content.

For in vivo rodent studies, Danazol is administered via oral gavage or intraperitoneal injection, with dosing regimens extrapolated from pharmacokinetic and toxicity studies (range: 10–100 mg/kg/day). All dosing protocols should include parallel vehicle and positive control arms. Analytical endpoints include serum LH/testosterone levels, tissue steroid content (LC-MS/MS), and histopathological scoring of target organs. These practices support robust, reproducible interrogation of androgen receptor and steroidogenesis pathways (Practical Guidance).

Conclusion & Outlook

Danazol (SKU C3644) delivers a rigorously characterized tool for probing androgen receptor signaling and steroidogenesis inhibition. Its mechanistic specificity, validated solubility, and purity benchmarks support its utility in translational endocrinology and oncology research. APExBIO’s high-purity Danazol delivers reproducibility and mechanistic clarity. Future studies may further define Danazol’s role in disease modeling and therapeutic screening, especially in HPG axis dysregulation and hormone-responsive cancers. Researchers are encouraged to consult both product documentation and current literature for protocol optimization and to ensure experimental alignment with Danazol’s validated mechanisms.